ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Transcranial photobiomodulation for the treatment of chemobrain: new perspectives from a pilot study.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to study the effect of transcranial stimulation with photobiomodulation (tPBM) in patients suffering from chemobrain.
methodPatients referred to a consultation dedicated to the management of post-chemotherapy cognitive impairment were included. The FACT-Cog (overall score and subscale) French version was used to assess perceived cognitive impairment and impact on quality of life for each patient before and at the end of tPBM treatment. All patients included were treated for chemobrain using transcranial stimulation by PBM for a minimum of 10 weeks (10 sessions, 1 session per week). The PBM consisted of transcranial stimulation delivered using a Vielight Neuro Duo 4® PBM device (in Gamma mode) for 20 min. Differences between pre- and post-treatment proportions were assessed with the McNemar test for paired data. Differences between FACT-Cog scores (total score and subscale) were assessed by the Wilcoxon signed-rank test.
resultsThirty-one women were included (mean age 52.1 ± 9.0 years). Mean total FACT-Cog score prior to tPBM was 63.3 ± 19.8. After the course of tPBM sessions, the mean total FACT-Cog score was 101.2 ± 20.1 (p < 0.001). Twenty-nine patients improved cognitive performance and, in 9 patients (29.0%), the FACT-Cog score had normalized. There was no significant difference between the proportion with anxiety or depression before vs after tPBM (p = 0.22 for anxiety, p = 0.62 for depression).
conclusionTranscranial stimulation by PBM shows therapeutic perspectives for the management of chemobrain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.